Niclosamide: STAT3 Inhibitor & Anticancer Research Guide

Niclosamide is a small-molecule inhibitor of the STAT3 signaling pathway that suppresses STAT3 activation, nuclear translocation, and transactivation while also inhibiting mTORC1 signaling and inducing autophagy, making it a multifunctional tool compound for cancer biology research.

Primary Target

STAT3 signaling pathway (inhibits activation, nuclear translocation, and transactivation)

Selectivity Profile

Selective for STAT3 over STAT1, STAT5, JAK1, JAK2, and Src kinases

Secondary Mechanism

Reversible inhibitor of mTORC1 signaling (FRAP inhibitor); stimulates autophagy in vitro

Cellular Effects

Induces cell growth inhibition, apoptosis, and cell cycle arrest in cancer cells with constitutively active STAT3

Antineoplastic Activity

Displays antineoplastic effects in acute myelogenous leukemia (AML) stem cells

Product SKU

N130841 (Aladdin Scientific)

Mechanism of Action: STAT3 Pathway Inhibition

Niclosamide exerts its primary pharmacological activity through potent inhibition of the Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathway. STAT3 is a latent cytoplasmic transcription factor that, upon activation by upstream kinases such as JAK1 and JAK2, undergoes phosphorylation, dimerization, and nuclear translocation to drive the transcription of genes regulating cell proliferation, survival, and immune evasion.

Niclosamide disrupts this cascade at multiple levels: it inhibits the phosphorylation-dependent activation of STAT3, prevents its nuclear translocation, and blocks its transactivation of target gene promoters. Critically, niclosamide demonstrates meaningful selectivity for STAT3 over closely related family members STAT1 and STAT5, as well as over upstream kinases JAK1, JAK2, and Src. This selectivity profile makes niclosamide a valuable tool compound for dissecting STAT3-specific biology in cellular models without confounding off-target suppression of parallel JAK-STAT branches.

Downstream consequences of STAT3 inhibition by niclosamide include suppressed transcription of STAT3 target genes encoding anti-apoptotic proteins, cell-cycle regulators, and angiogenic factors, collectively resulting in measurable growth inhibition, apoptosis induction, and cell cycle arrest—particularly in cancer cell lines harboring constitutively active STAT3.

mTORC1/FRAP Inhibition and Autophagy Induction

Beyond its STAT3-directed activity, niclosamide functions as a reversible inhibitor of mTORC1 signaling—the FRAP (FKBP12-rapamycin-associated protein, also known as mTOR) complex responsible for integrating nutrient, energy, and growth factor signals to control anabolic processes. By reversibly attenuating mTORC1 activity, niclosamide mimics a nutrient-deprivation state within the cell.

A direct cellular consequence of mTORC1 suppression is the induction of autophagy—the lysosomal degradation pathway through which cells recycle damaged organelles and macromolecules. Niclosamide has been shown to stimulate autophagy in vitro, an effect attributable at least in part to its mTORC1 inhibitory activity. Autophagy induction can be experimentally verified using standard assays including LC3-I to LC3-II conversion by immunoblot, autophagic flux assays with bafilomycin A1, and fluorescent LC3 puncta formation.

Researchers investigating the interplay between STAT3 signaling, mTORC1 activity, and autophagy in cancer cell biology will find niclosamide a uniquely dual-targeting reagent that permits simultaneous interrogation of both pathways within a single experimental system. Care should be taken to deconvolve STAT3-dependent versus mTORC1-dependent phenotypes using appropriate pathway-specific controls.

Antineoplastic Activity in AML and Cancer Models

Niclosamide displays documented antineoplastic effects in acute myelogenous leukemia (AML) stem cells, a therapeutically challenging population known for their role in disease relapse and chemoresistance. AML stem cells frequently exhibit constitutive activation of STAT3 and aberrant mTOR signaling, both of which are targeted by niclosamide, providing a mechanistic rationale for its observed activity in this cellular compartment.

More broadly, niclosamide-induced inhibition of STAT3 transcriptional activity leads to downregulation of key oncogenic targets including survivin, cyclin D1, Bcl-2, and VEGF—proteins whose dysregulated expression underpins proliferation and survival in numerous solid and hematological malignancies. In experimental cancer models, these effects manifest as measurable decreases in viable cell number, increased annexin V positivity (indicative of apoptosis), and flow-cytometric evidence of cell cycle arrest.

When designing niclosamide experiments in cancer cell lines, researchers should: (1) confirm constitutive STAT3 phosphorylation status in the chosen cell line prior to treatment; (2) include appropriate solvent (DMSO) vehicle controls; (3) validate STAT3 target gene suppression by qRT-PCR or immunoblot; and (4) assess viability using complementary methods such as MTT/CCK-8 and colony formation assays to obtain a comprehensive picture of the antiproliferative response.

Laboratory Handling, Solubility, and Storage Recommendations

Niclosamide (MW 327.12 g/mol; CAS 50-65-7) is a halogenated salicylanilide that is sparingly soluble in aqueous buffers but soluble in organic solvents including DMSO and ethanol. For cell-based assays, stock solutions are typically prepared in DMSO at concentrations of 10–100 mM and diluted into culture medium immediately prior to use to achieve final DMSO concentrations ≤0.1% v/v to avoid solvent cytotoxicity artifacts.

Storage: Store at –20 °C in a tightly sealed, light-protected container under inert atmosphere or desiccated conditions. Niclosamide is stable for extended periods when stored correctly; however, researchers should verify purity by HPLC or TLC before use in quantitative experiments, particularly from thawed aliquots. Prepare single-use aliquots to minimize freeze-thaw cycling.

Safety: Niclosamide should be handled in a well-ventilated fume hood with appropriate PPE (lab coat, nitrile gloves, safety glasses). Consult the current Safety Data Sheet (SDS) for complete hazard, first-aid, and disposal information before use. Waste containing niclosamide must be disposed of in accordance with local institutional and regulatory guidelines for chemical waste.

Quality note: Aladdin Scientific's Niclosamide (SKU N130841) is intended for research use only and is not suitable for human or veterinary therapeutic use without further validation.

Frequently asked questions

What is the primary mechanism by which niclosamide inhibits STAT3?

Niclosamide inhibits STAT3 by blocking its phosphorylation-dependent activation, preventing its nuclear translocation, and suppressing its transactivation of target gene promoters. It demonstrates selectivity for STAT3 over related family members STAT1 and STAT5 as well as over JAK1, JAK2, and Src kinases.

Does niclosamide affect pathways other than STAT3?

Yes. In addition to STAT3 inhibition, niclosamide acts as a reversible inhibitor of mTORC1 (FRAP) signaling and stimulates autophagy in vitro. Researchers should account for these dual mechanisms when interpreting experimental results and use appropriate pathway-specific controls.

Which cancer model is specifically associated with niclosamide's antineoplastic activity?

Niclosamide has been shown to display antineoplastic effects specifically in acute myelogenous leukemia (AML) stem cells. Its activity in this model is mechanistically consistent with its inhibition of constitutively active STAT3 and aberrant mTOR signaling, both of which are frequently observed in AML stem cell populations.

How should niclosamide stock solutions be prepared for cell-based assays?

Niclosamide stock solutions are typically prepared in DMSO (e.g., 10–100 mM) and then diluted directly into culture medium immediately before use, keeping the final DMSO concentration at or below 0.1% v/v to minimize solvent-related cytotoxicity. Prepare single-use aliquots and store at –20 °C to avoid repeated freeze-thaw cycles.

Is Aladdin Scientific's niclosamide (N130841) suitable for in vivo or clinical use?

No. Niclosamide (SKU N130841) from Aladdin Scientific is manufactured and qualified for research use only. It is not intended for human therapeutic, veterinary, or clinical diagnostic applications without additional validation, regulatory review, and appropriate GMP manufacturing.

References

1. Niclosamide product description. Aladdin Scientific, SKU N130841.
2. Li Y, et al. Niclosamide, an antihelminthic drug, inhibits Stat3 signaling and induces apoptosis in human breast cancer cells. [Journal and volume details to be verified]
3. Yo YT, et al. Niclosamide and its analogues inhibit FRAP/mTOR signaling and stimulate autophagy. [Journal and volume details to be verified]
4. Jin Y, et al. Antiparasitic drug niclosamide displays antineoplastic activity in AML stem cells. [Journal and volume details to be verified]

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.